Its finals time ....
... and OBJ keep kicking goals ....
NEW WORK PLAN WITH P&G TARGETING IN‐SHAVE BENEFIT
Breakthrough opportunity in large scale shaving market
First expansion for OBJ beyond skincare
OBJ technology returns positive results in second major P&G trial
Key P&G brands introduced to DCE technology Magnetic micro‐array drug delivery and product enhancement technology company OBJ Limited (ASX: OBJ), under its ongoing and expanding relationship with Procter & Gamble (P&G), has signed a new work plan targeting the area of in‐shave benefit.
The work plan sets out a program to quantify the opportunities for OBJ’s magnetic microarray technology to drive new benefits in men’s and women’s shaving products.
“In‐shave benefit is a sector where we see substantial opportunity for OBJ’s technology because consumers already have an applicator in their hands,” said Jeffrey Edwards, OBJ’s Managing Director.
“The blade is an ideal carrier for our microarray technology as it allows us to take full advantage of normal consumer behaviour and potentially deliver a range of new benefits without any additional steps or effort by customers.”
While being in a very early development stage, OBJ management believes its technology can excel in the shaving sector and generate benefits in what is an enormous available market. Second major human clinical trial by P&G Results have been released by P&G from a second major human clinical trial conducted by an independent US‐based Contract Research Organisation. The clinical study was designed to quantify the effect of OBJ technology on key biological functions of the skin.
The results showed that the OBJ magnetic microarrays delivered substantial statistical improvements in key skin barrier functions and skin health indices when compared to the same formulation delivered using an identical applicator without OBJ’s technology.
This large human clinical study represents a substantial investment by P&G in further validating OBJ’s technology while highlighting its ability to improve skin health and cosmetic benefits.
OBJ RELEASE 8 September 2015 Registered Office: 284 Oxford Street Leederville Western Australia 6007 Tel: +61 8 9443 3011 Fax: +61 8 9443 9960
www.obj.com.au ABN: 72 056 482 636 DCE applicator technology introduced Recent meetings with P&G in Cincinnati, USA have provided OBJ with the opportunity to demonstrate its new Dynamically Configurable Emulsion (DCE) technology to a number of key P&G brands. A number of these brands have expressed substantial interest in the new technology. The DCE technology is outside the scope of the existing P&G Product Development Agreement.
(20min delay)